Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Glaukos ( (GKOS) ) just unveiled an announcement.
On February 17, 2026, Glaukos reported record fourth-quarter 2025 net sales of $143.1 million, up 36% year over year, driven by a 42% surge in glaucoma revenue and 53% growth in U.S. glaucoma sales, while full-year 2025 revenue climbed 32% to $507.4 million. Despite higher sales and improved non-GAAP margins, the company posted a GAAP net loss of $133.7 million for the quarter and $187.7 million for the year, heavily impacted by a $112.9 million non-cash impairment tied to the Photrexa-to-Epioxa transition.
Non-GAAP metrics showed operational progress, with the quarterly non-GAAP operating loss narrowing to $16.4 million from $18.3 million a year earlier and full-year non-GAAP operating loss improving to $57.4 million from $93.3 million, supported by robust gross margins and continued R&D investment. Glaukos ended 2025 with $282.6 million in cash and no debt, and reaffirmed its 2026 net sales outlook of $600 million to $620 million, underscoring management’s confidence that new platforms such as iDose TR and Epioxa will drive sustained growth and reinforce its competitive position in ophthalmic therapies.
The most recent analyst rating on (GKOS) stock is a Buy with a $160.00 price target. To see the full list of analyst forecasts on Glaukos stock, see the GKOS Stock Forecast page.
Spark’s Take on GKOS Stock
According to Spark, TipRanks’ AI Analyst, GKOS is a Neutral.
The score is held back primarily by weak financial performance (ongoing losses and negative operating cash flow) and an earnings-based valuation signal that reflects those losses. Offsetting these are a constructive technical backdrop (longer-term uptrend) and a notably strong earnings call with record sales, raised guidance, and meaningful product milestones, albeit with reimbursement and franchise-transition risks.
To see Spark’s full report on GKOS stock, click here.
More about Glaukos
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company specializing in novel therapies for glaucoma, corneal disorders, and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery, markets the only FDA-approved corneal cross-linking therapy for keratoconus, and began commercial launch activities for its long-duration glaucoma implant iDose TR in 2024, while advancing a pipeline of dropless platform technologies for chronic eye conditions.
Glaukos focuses on developing and commercializing procedures and drugs that aim to improve standards of care in ophthalmology, targeting chronic eye diseases that require sustained treatment. Its portfolio and pipeline position the company in high-need specialty niches within eye care, where innovative, device-enabled pharmaceutical delivery and corneal therapies can command premium pricing and support durable growth.
Summary
Average Trading Volume: 792,030
Technical Sentiment Signal: Buy
Current Market Cap: $6.29B
Find detailed analytics on GKOS stock on TipRanks’ Stock Analysis page.